Clinical Trials Logo

Anal Squamous Cell Carcinoma clinical trials

View clinical trials related to Anal Squamous Cell Carcinoma.

Filter by:

NCT ID: NCT06050707 Recruiting - Clinical trials for Anal Squamous Cell Carcinoma

MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach

MAESTRO
Start date: September 29, 2023
Phase: Phase 2
Study type: Interventional

The proposed study is a phase II, single arm, open-label trial of MR-guided radiation therapy (RT) with risk stratified RT dose selection in patients with anal cancer. Based on previous data, a risk adaptive treatment approached is proposed in 4 groups: Low risk, standard risk, intermediate risk, and high risk. Human papillomavirus (HPV) DNA will be analyzed to identify novel biomarkers that predict chemoradiotherapy (CRT) response and toxicity.

NCT ID: NCT05838391 Recruiting - Clinical trials for Anal Squamous Cell Carcinoma

Adaptive Radiation in Anal Cancer

Start date: May 18, 2023
Phase: N/A
Study type: Interventional

This is a 20 patient pilot study to examine the feasibility of dose-adapted radiation therapy for the treatment of locally advanced anal squamous cell cancer. The tumor and a patient's anatomy may change during radiation treatment and daily adaption of the radiation plan (i.e., a new daily plan based on the anatomy of the day) may help to maximize the dose to the tumor and minimize the radiation dose to the normal surrounding organs.

NCT ID: NCT05582031 Withdrawn - Clinical trials for Colorectal Neoplasms

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

REFIT-MSS
Start date: April 30, 2023
Phase: Phase 2
Study type: Interventional

REFIT-MSS is a non-randomized, multicenter, open-label, multi-cohort, 2-stage, phase II trial to evaluate the efficacy and safety of regorafenib in combination with tislelizumab (referred as Rego-Tisle) in adult patients with select advance, previously treated, Mismatch Repair-Proficient/Microsatellite (pMMR/MSS) stable solid cancers. The multi-cohort design will allow for the examination of 8 separate cohorts of different cancers to determine whether further examination may be warranted in the individual indications.

NCT ID: NCT05438836 Recruiting - Anal Cancer Clinical Trials

Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer

ROAR-A
Start date: January 1, 2022
Phase:
Study type: Observational

A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).

NCT ID: NCT05374252 Recruiting - Anal Cancer Clinical Trials

Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients

Start date: May 7, 2022
Phase: Phase 3
Study type: Interventional

This is a phase III, multi-center, double-blind randomized controlled trial assessing the efficacy and safety of concurrent mitomycin C/5-Fu chemotherapy and long-course IMRT combined with PD-1 antibody Sintilimab for locally advanced anal canal squamous carcinoma patients, by comparing an experiment group (traditional chemoradiotherapy with PD-1 antibody Sintilimab) with a control group (traditional treatment without Sintilimab).

NCT ID: NCT05328765 Recruiting - HIV Infections Clinical Trials

A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection

ACTION HIV
Start date: June 9, 2023
Phase:
Study type: Observational

Due to the scarcity of data on prognostic and predictive influence on CCA, epidemiological studies evaluating these factors need to be developed in patients with CCA. Therefore, the investigators want to evaluate the profile of patients in the real world and from various parts of the world, describing prognostic factors such as CD4 dosage, time of HIV infection, evaluation of viral load, diagnosis of AIDS, geographic region of diagnosis and treatment, clinical staging, medications concomitant with QRT (risk of drug interactions), comorbidities (possible impact on dose-intensity), use of HAART, time of use of HAART, radiotherapy modality (conventional 3D vs Modulated Beam Intensity [IMRT], response to Nigro vs CTII regimens, as well as comparing clinical outcomes with patients without HIV infection.

NCT ID: NCT05130073 Completed - Clinical trials for Anal Squamous Cell Carcinoma

4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer

Start date: July 31, 2019
Phase:
Study type: Observational

This study determines whether a positron emission tomography (PET)/computed tomography (CT) 4-point scoring system may predict overall survival for anal squamous cell cancer patients. A 4-point scoring system involving imaging scans may help to predict how patients with anal squamous cell cancer respond to chemoradiation therapy.

NCT ID: NCT05060471 Enrolling by invitation - Anal Cancer Clinical Trials

PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients

Start date: September 8, 2021
Phase: Phase 2
Study type: Interventional

Locally Advanced Anal Canal Squamous Carcinoma Patients will be enrolled and given four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab. Treatment outcomes and toxicities will be evaluated.

NCT ID: NCT04929028 Recruiting - HIV Infection Clinical Trials

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Start date: August 9, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects of chemotherapy and intensity modulated radiation therapy in treating patients with low-risk HIV-associated anal cancer, and nivolumab after standard of care chemotherapy and radiation therapy in treating patients with high-risk HIV-associated anal cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with radiation therapy may kill more tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab after standard of care chemotherapy and radiation therapy may help reduce the risk of the tumor coming back.

NCT ID: NCT04616196 Completed - Colorectal Cancer Clinical Trials

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Start date: October 30, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2, open-label multicenter study evaluating NKTR-255 as a monotherapy and together with cetuximab in patients with head and neck squamous cell carcinoma (HNSCC), colorectal carcinoma (CRC), cutaneous squamous cell carcinoma (cSCC), anal cell carcinoma (ASCC) and cervical cancer. The recommended phase 2 dose of NKTR-255, determined in the dose escalation phase (Phase 1b), will be used to treat patients in Phase 2 of this study.